title: Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients.
abstract: BACKGROUND
  Azathioprine (AZA) is widely used to treat corticosteroid (CS)-dependent IBD patients but evidence supporting its use in Asian IBD patients is limited. We evaluated the efficacy of AZA in a single-center cohort of CS-dependent Asian IBD patients.
  
  
  METHODS
  Patients treated with AZA were identified from our registry and the medical records were reviewed. Inclusion criterion was: first course of AZA and treatment duration ≥ 6 months. Clinical response was assessed at 6 months and classified as complete response, partial response, and nonresponse. Factors associated with response (age, gender, ulcerative colitis [UC] extent, Crohn's disease [CD] behavior, ethnicity, concomitant 5-aminosalicylates/sulfasalazine, baseline activity, disease duration, leukocyte count, mean corpuscular volume, and AZA dose) were analyzed using the chi-square or Mann-Whitney U-test. Probability of sustained remission was estimated using the Kaplan-Meier method. Differences in survival curves between factors were tested with log-rank tests.
  
  
  RESULTS
  Sixty-four patients were included. At baseline the median age was 37.5 (range, 15-76) years, 50% male, 59.4% Chinese, 50% CD, 50% UC, and mean CS dose 20.2 (SD 10.9) mg. At month 6, complete response was 48.4% (95% confidence interval [CI], 36.7-61.3), partial response 45.1% (95% CI, 32.8-58.3), and nonresponse 7.8% (95% CI, 2.6-17.3). Partial responders had mean CS dose reductions of 11.7 mg (95% CI, 7.2-16.4, P < 0.001). The proportion of patients with sustained remission was 0.87 (95% CI, 0.73-1.0) at 2 years, 0.76 (95% CI, 0.57-0.95) at 3 years, and 0.61 (95% CI, 0.30-0.91) at 5 years of AZA treatment. Female gender was positively associated with sustained remission.
  
  
  CONCLUSIONS
  Our study demonstrates the short- and long-term effectiveness of AZA therapy among CS-dependent Asian IBD patients.
authors.affiliation: Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore. ktjthia@gmail.com
authors.forename: Kelvin T
authors.initials: KT
authors.lastname: Thia
authors.forename: Meiqin
authors.initials: M
authors.lastname: Li
authors.forename: Khoon-Lin
authors.initials: KL
authors.lastname: Ling
authors.forename: San-Choon
authors.initials: SC
authors.lastname: Kong
authors.forename: Choon-Jin
authors.initials: CJ
authors.lastname: Ooi
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D044466:Asian People; D001379:Azathioprine / Q000627:therapeutic use*; D015331:Cohort Studies; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D001379:Azathioprine